Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Gastroenterology  |  Family Medicine

Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Fecal Incontinence Clinical Trials

A listing of Fecal Incontinence medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.


Found (28) clinical trials

A Study of E7386 in Participants With Advanced Solid Tumor Including Colorectal Cancer (CRC)

The study will be conducted in 2 parts: dose escalation part and expansion part. The study will include Pre-treatment Phase, Treatment Phase, and Extension Phase (in expansion part only). Eligible participants from Pre-Treatment Phase (screening period) will enter into the Treatment Phase to receive E7386. After Treatment Phase, participants will ...


Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma

The purpose of this research study to find out if the drug trametinib in combination with ruxolitinib is safe, tolerable and has beneficial effects in people who has certain type of cancers including the type that you have. Patients with RAS mutant colorectal cancer and pancreatic adenocarcinoma are invited to ...


A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies

The study will be conducted in two segments. The first segment of the study, designated Phase 1a, will be a dose escalation design in order to assess the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of ascending doses of AZD4635 as monotherapy, in combination with durvalumab or durvalumab plus ...


A First-in-Human Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors

This is a Phase 1, first-in-human, open-label dose-escalation study to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) and assess the DLT of JAB-3312. It is anticipated that approximately 24 subjects will be enrolled in the dose-escalation phase of the study. JAB-3312 will be administered orally ...


A Study of XmAb 20717 in Subjects With Selected Advanced Solid Tumors

This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb20717, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity of XmAb20717 in subjects with selected advanced solid tumors.


Oral STAT3 Inhibitor TTI-101 in Patients With Advanced Cancers

Signal transducer and activator of transcription 3 (STAT3) is a member of a family of seven closely related proteins responsible for transmission of peptide hormone signals from the extracellular surface of cells to the nucleus. STAT3 is a master regulator of most key hallmarks and enablers of cancer, including cell ...


Phase I Trial of VS-6063 and RO5126766.

This is a multi-centre, investigator-initiated, dose escalation, Phase I trial of the combination of the FAK inhibitor, VS-6063, and the dual RAF/MEK inhibitor, RO5126766 in patients with advanced solid tumours. RO5126766 is the same compound to CH5126766. There are two parts to this study, the dose escalation phase and the ...


A Safety Study of SGN-CD47M in Patients With Solid Tumors

This is a dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and antitumor activity of SGN-CD47M in adults with advanced solid tumors. The study will be conducted in 2 parts: Part A - Dose escalation: Up to approximately 25 patients will be treated to evaluate the safety, tolerability, ...


A Study of SGN-CD228A in Advanced Solid Tumors

This study is designed to evaluate the safety, tolerability, PK, and antitumor activity of SGN-CD228A in select advanced solid tumors. The study will include dose escalation and dose expansion, with multiple disease-specific expansion cohorts.


A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)

This study will determine the safety and tolerability and establish a preliminary recommended Phase 2 dose of V941(mRNA-5671/V941) as a monotherapy and in combination with pembrolizumab infusion.